Treatment Method

The therapy, called SNIPR001, was developed by the Danish biotech company SNIPR Biome . It consists of a cocktail of four bacteriophages (viruses that specifically infect bacteria) engineered with CRISPR-Cas9 gene-editing machinery that cleaves the bacterial DNA, killing the E. coli . The treatment was administered under an FDA emergency Investigational New Drug (IND) application using three concurrent routes :

• Intravenous (systemic delivery)
• Topical (applied directly to abdominal cutaneous wounds)
• Intralesional (injected directly into the intra-abdominal malakoplakia mass)

This was combined with continued antibiotics, ascorbic acid (vitamin C), and bethanechol as adjunctive therapy .

Clinical Results

The response was rapid, sustained, and well-tolerated :

The patient survived and recovered from a life-threatening, otherwise untreatable infection .

How CRISPR Made the Difference

Wild-type (unmodified) bacteriophages alone often fail because bacteria can evolve resistance or the phages' killing efficiency is limited. SNIPR001's CRISPR-Cas9 payload provides a precision-guided DNA-destruction mechanism that dramatically increases bacterial killing and reduces the chance of resistance emerging . The phages deliver the CRISPR system directly into the bacterial cells, where it targets and cleaves conserved essential sequences in the E. coli genome .

Future Implications

• Proof of concept for CRISPR-phage therapy in humans: This is the first reported human case where an engineered CRISPR-armed phage cocktail successfully treated a deep-seated, drug-resistant bacterial infection .
• New option for antimicrobial-resistant infections: The case demonstrates a salvage pathway for patients with MDR pathogens who have exhausted all antibiotic options — a growing global crisis .
• Regulatory and access pathway: The FDA's emergency IND mechanism allowed rapid deployment of an unapproved therapy for a compassionate-use case, potentially setting a precedent .
• Broader applicability: SNIPR001 targets E. coli systemically, but the same platform could be adapted to other Gram-negative and Gram-positive pathogens by engineering phages with matching host ranges and CRISPR guides .

Key caveat: This is a single-patient expanded-access case, not a controlled clinical trial . Larger Phase 1/2 trials of SNIPR001 are ongoing, and the therapy has not yet received regulatory approval for routine clinical use . The adjunctive role of concurrent antibiotics and other co-therapies means the exact contribution of the phages alone is not fully disentangled.

Treatment Method

The therapy, called SNIPR001, was developed by the Danish biotech company SNIPR Biome . It consists of a cocktail of four bacteriophages (viruses that specifically infect bacteria) engineered with CRISPR-Cas9 gene-editing machinery that cleaves the bacterial DNA, killing the E. coli . The treatment was administered under an FDA emergency Investigational New Drug (IND) application using three concurrent routes :

• Intravenous (systemic delivery)
• Topical (applied directly to abdominal cutaneous wounds)
• Intralesional (injected directly into the intra-abdominal malakoplakia mass)

This was combined with continued antibiotics, ascorbic acid (vitamin C), and bethanechol as adjunctive therapy .

Clinical Results

The response was rapid, sustained, and well-tolerated :

The patient survived and recovered from a life-threatening, otherwise untreatable infection .

How CRISPR Made the Difference

Wild-type (unmodified) bacteriophages alone often fail because bacteria can evolve resistance or the phages' killing efficiency is limited. SNIPR001's CRISPR-Cas9 payload provides a precision-guided DNA-destruction mechanism that dramatically increases bacterial killing and reduces the chance of resistance emerging . The phages deliver the CRISPR system directly into the bacterial cells, where it targets and cleaves conserved essential sequences in the E. coli genome .

Future Implications

• Proof of concept for CRISPR-phage therapy in humans: This is the first reported human case where an engineered CRISPR-armed phage cocktail successfully treated a deep-seated, drug-resistant bacterial infection .
• New option for antimicrobial-resistant infections: The case demonstrates a salvage pathway for patients with MDR pathogens who have exhausted all antibiotic options — a growing global crisis .
• Regulatory and access pathway: The FDA's emergency IND mechanism allowed rapid deployment of an unapproved therapy for a compassionate-use case, potentially setting a precedent .
• Broader applicability: SNIPR001 targets E. coli systemically, but the same platform could be adapted to other Gram-negative and Gram-positive pathogens by engineering phages with matching host ranges and CRISPR guides .

Key caveat: This is a single-patient expanded-access case, not a controlled clinical trial . Larger Phase 1/2 trials of SNIPR001 are ongoing, and the therapy has not yet received regulatory approval for routine clinical use . The adjunctive role of concurrent antibiotics and other co-therapies means the exact contribution of the phages alone is not fully disentangled.